ArticleNature communications2014
Optical control of insulin release using a photoswitchable sulfonylurea.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 129 citations in OpenAlex.
- Article
- A Platform for the Development of Highly Red-Shifted Azobenzene-Based Optical Tools.Angewandte Chemie (International ed. in English) · 2025Article
- Therapeutic Potential of Infrared and Related Light Therapies in Metabolic Diseases.International journal of molecular sciences · 2025Review
- Article
- Optogenetic therapeutic strategies for diabetes mellitus.Journal of diabetes · 2024Review
- Synthetic Biology Meets CaCells · 2024Review
- Fine-tuned photochromic sulfonylureas for optical control of beta cell CaDiabetic medicine : a journal of the British Diabetic Association · 2023Article
- Designing Covalent Organic Framework-Based Light-Driven Microswimmers toward Therapeutic Applications.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Comparison of decision tree with common machine learning models for prediction of biguanide and sulfonylurea poisoning in the United States: an analysis of the National Poison Data System.BMC medical informatics and decision making · 2023Article
- All Visible Light Photoswitch Based on the Dimethyldihydropyrene Unit Operating in Aqueous Solutions with High Quantum Yields.JACS Au · 2023Article
- Comprehensive Evaluation of Probiotic Property, Hypoglycemic Ability and Antioxidant Activity of Lactic Acid Bacteria.Foods (Basel, Switzerland) · 2022Article
- Advances and opportunities in the exciting world of azobenzenes.Nature reviews. Chemistry · 2022Review
- Photo-Switchable Sulfonylureas Binding to ATP-Sensitive Potassium Channel Reveal the Mechanism of Light-Controlled Insulin Release.The journal of physical chemistry. B · 2021Article
- β-Cell Pathophysiology: A Review of Advanced Optical Microscopy Applications.International journal of molecular sciences · 2021Review
- A fine-tuned azobenzene for enhanced photopharmacology in vivo.Cell chemical biology · 2021Article
- Molecular photoswitches in aqueous environments.Chemical Society reviews · 2021Review
- Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug.International journal of molecular sciences · 2021Article
- Development of High-Performance Pyrimidine Nucleoside and Oligonucleotide Diarylethene Photoswitches.Angewandte Chemie (International ed. in English) · 2021Article
- Using High Molecular Precision to Study Enzymatically Induced Disassembly of Polymeric Nanocarriers: Direct Enzymatic Activation or Equilibrium-Based Degradation?Macromolecules · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 5 countries.
Funding
Abstract
Sulfonylureas are widely prescribed for the treatment of type 2 diabetes mellitus (T2DM). Through their actions on ATP-sensitive potassium (KATP) channels, sulfonylureas boost insulin release from the pancreatic beta cell mass to restore glucose homeostasis. A limitation of these compounds is the elevated risk of developing hypoglycemia and cardiovascular disease, both potentially fatal complications. Here, we describe the design and development of a photoswitchable sulfonylurea, JB253, which reversibly and repeatedly blocks KATP channel activity following exposure to violet-blue light. Using in situ imaging and hormone assays, we further show that JB253 bestows light sensitivity upon rodent and human pancreatic beta cell function. Thus, JB253 enables the optical control of insulin release and may offer a valuable research tool for the interrogation of KATP channel function in health and T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.